Denis Schrier Email

VP, Toxicology . Inozyme Pharma

Current Roles

Employees:
62
Revenue:
$9.8M
About
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Inozyme Pharma Address
321 Summer Street
Boston, MA
United States
Inozyme Pharma Email

Past Companies

Inozyme PharmaVice President, Toxicology
CLAD Preclinical Development, LLCPrincipal Scientist
Alexion PharmaceuticalsExecutive Director, Non Clinical Pharma/Toxicology

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.